MEHD7945A is a phage-derived, human IgG1 monoclonal antibody. It was developed using a novel antibody-engineering platform to allow specific high-affinity binding to EGFR or HER3 with either antigen-binding fragment (Fab). When bound to these receptors, MEHD7945A blocks their ligands from binding, resulting in inhibition of ligand-driven signaling from EGFR/EGFR, EGFR/HER2, EGFR/HER3, and HER2/HER3 dimer pairs.
Drug Code Name
MEHD7945A